Danske Invest

MediLife Fund G

Morningstar Rating™ : - ESG-funds - ISIN: FI0008802947
Documents
Factsheet
Key Investor Information Document
Price list
Fund regulations
Investor notification
Prospectus
Sustainability-related disclosure
Investor rights

2.56769

NAV as of 23.09.2022

+0.48%

Return 1 day

-5.61%

Return 1 month

-7.20%

Return (year-to-date)

Objectives and investment policy

Objectives

The target of investment activities is to achieve long-term value increase on the invested assets through active asset management pursuant to the Act on Common Funds and the fund's regulations.

Investment policy

The assets are invested in publicly traded equities and equity-linked securities of pharmaceutical, healthcare and biotechnology companies globally. The assets may also be invested in securities whose issuer's primary business is related to ageing or quality of life, or serves or supports these sectors. The fund is categorized under SFDR as article 8 and promotes environmental and social characteristics, as well as good governance practices, through screening, restrictions, investment analysis and decision-making as well as active ownership. The fund follows Danske Invest’s responsible investment policy. The returns on the fund's investments, such as dividends and interest, will be reinvested. The fund's base currency is the euro.

It is generally expected that the fund's holdings, and therefore its performance, may differ significantly from those of the benchmark. The fund is suitable for investors who wish to invest globally in pharmaceutical and other healthcare sector companies and who seek high returns, while tolerating substantial value fluctuations or even decreases. The fund is suitable as part of a diversified investment portfolio. Investors may subscribe for and redeem fund units on every banking day.


Recommendation: This fund may not be appropriate for investors who plan to withdraw their money within 7 years.

ESG-funds (Article 8)
Funds that promote environmental (E) and/or social (S) factors and ensure good governance (G) practices are called ESG funds at Danske Invest. These funds promote E/S characteristics through screening, restrictions, investment analysis, and active ownership, but they do not have sustainable investments as their objective. The funds integrate ESG by systematically identifying and addressing sustainability factors during the investment process.

ESG funds comply with Article 8 of the EU regulation on sustainability‐related disclosures in the financial services sector.

Return

MediLife Fund G
Benchmark
Return
Annual return
Monthly excess return compared to benchmark
1 year
3 years
5 years
10 years
Since launch

to
Compare with other fund ...
2030 Fund DDanske Invest
2030 Fund GDanske Invest
2040 Fund DDanske Invest
2040 Fund GDanske Invest
Bond Fund DDanske Invest
Bond Fund GDanske Invest
Bond Fund I DDanske Invest
Bond Fund I GDanske Invest
China Fund DDanske Invest
China Fund GDanske Invest
Compass 25 Fund DDanske Invest
Compass 25 Fund GDanske Invest
Compass 50 Fund DDanske Invest
Compass 50 Fund GDanske Invest
Compass 75 Fund DDanske Invest
Compass 75 Fund GDanske Invest
Compass Equity Fund DDanske Invest
Compass Equity Fund GDanske Invest
Compass Liquidity Fund DDanske Invest
Compass Liquidity Fund GDanske Invest
ESG Equities Fund DDanske Invest
ESG Equities Fund GDanske Invest
Eastern Europe Convergence Fund DDanske Invest
Eastern Europe Convergence Fund GDanske Invest
Eliksir Fund of Hedge Funds G (AIF)Danske Invest
Emerging Markets Debt Fund D (AIF)Danske Invest
Emerging Markets Debt Fund G (AIF)Danske Invest
Emerging Markets Equity Fund DDanske Invest
Emerging Markets Equity Fund GDanske Invest
Emerging and Frontier Markets Class ADanske Invest SICAV
Euro Corporate Bond Fund DDanske Invest
Euro Corporate Bond Fund GDanske Invest
Euro Government Bond Index Fund GDanske Invest
Euro High Yield Fund DDanske Invest
Euro High Yield Fund GDanske Invest
Europe Enhanced Index Fund D (AIF)Danske Invest
Europe Enhanced Index Fund G (AIF)Danske Invest
Europe High Dividend Fund DDanske Invest
Europe High Dividend Fund GDanske Invest
Europe Small Cap Fund DDanske Invest
Europe Small Cap Fund GDanske Invest
European Corporate Sustainable Bond Class ADanske Invest SICAV
European Equity Fund DDanske Invest
European Equity Fund GDanske Invest
Finnish Equity Fund DDanske Invest
Finnish Equity Fund GDanske Invest
Finnish Equity Fund I DDanske Invest
Finnish Equity Fund I GDanske Invest
Global ESG 130/30 Class A-eurDanske Invest SICAV
Global Emerging Markets, osuuslaji EURDanske Invest
High Yield Fund G (AIF)Danske Invest
India Fund DDanske Invest
India Fund GDanske Invest
Institutional Liquidity Fund DDanske Invest
Institutional Liquidity Fund GDanske Invest
Institutional Liquidity Plus Fund DDanske Invest
Institutional Liquidity Plus Fund GDanske Invest
Japanese Equity Fund DDanske Invest
Japanese Equity Fund GDanske Invest
Kehittyvät Korkomarkkinat Paikallisvaluutta, osuuslaji EURDanske Invest
Kehittyvät Korkomarkkinat Paikallisvaluutta, osuuslaji EUR WDanske Invest
Liquidity Fund DDanske Invest
Liquidity Fund GDanske Invest
MediLife Fund DDanske Invest
Multi Asset Inflation Strategy Class ADanske Invest SICAV
Neutral Fund DDanske Invest
Neutral Fund GDanske Invest
Pohjoisen Yrityslainat, osuuslaji EUR hDanske Invest
Reaalikorko Maailma, osuuslaji EUR hDanske Invest
Technology Index Fund DDanske Invest
Technology Index Fund GDanske Invest
USA Index Fund DDanske Invest
USA Index Fund GDanske Invest
USA Index Fund I DDanske Invest
USA Index Fund I GDanske Invest
Past performance is not a reliable indicator of future results. Future returns may be negative. The return may increase and decrease as a result of currency fluctuations if the fund is issued in a currency other than the currency used in the country in which you are domiciled.

Risk indicator

Lower risk

Higher risk

Typically lower return

Typically higher return

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

The indicator illustrates the typical correlation between the risk and your potential return of the investment. The categorization is determined by the fluctuations in the fund's net asset value over the past five years and/or representative data.

Significant historical volatility equals high risk and low volatility equals lower risk. Please note that the fund’s categorization is not constant and the categorization may change over time. Historical performance data is not necessarily a reliable indicator of the future risk profile.

The risk indicator is purely a mathematical calculation and it does not take devaluations, political intervention and sudden fluctuations in interest rates and currencies into account. Risk class 1 is not a risk-free investment.
 

Value of
Click to change the amount

0 years
years
10 years
years

of which n/a € in dividends.
Total charges during the period:
n/a €.

Past performance is not a reliable indicator of future results. Future returns may be negative. The return may increase and decrease as a result of currency fluctuations if the fund is issued in a currency other than the currency used in the country in which you are domiciled.
Show table

Value of EUR 100

PeriodeVærdi
1 year runningEUR 100.97
3 years runningEUR 146.01
5 years runningEUR 177.18
7 years runningEUR 176.41
10 years runningEUR 369.78
Past performance is not a reliable indicator of future results. Future returns may be negative. The return may increase and decrease as a result of currency fluctuations if the fund is issued in a currency other than the currency used in the country in which you are domiciled.
Show calculator

Manager

Team Managed (Allianz)

Allianz Global Investors

Allianz Global Investors U.S. LLC is a global asset management company with nearly 40 years of experience. The company is owned by Allianz Asset Management AG, which in turn is owned by the the German insurance company Allianz, SE. The company has offices in the US, Europe, Asia and Australia.

Allianz is advisor for Danske Invest on a.o. technology equities and the team advising Danske Invest is located in San Francisco. The equity team focuses on companies that have sustained earnings growth, strong balance sheets and reasonable pricing. Furthermore, the team focuses on companies that deliver new products through research and product development.

Asset allocation as of 29.07.2022


Please note that all holdings are delayed with 1 month.
MediLife Fund G

Holdings as of 29.07.2022

Name of investment/security Weight Type Currency Country ISIN code
Thermo Fisher Scientific Inc 000000000000005.485.48% Equities USD USA US8835561023
Eli Lilly & Co. 000000000000005.255.25% Equities USD USA US5324571083
AstraZeneca (ADR) 000000000000005.065.06% Equities USD USA US0463531089
Merck & Co. Inc. (US) 000000000000004.684.68% Equities USD USA US58933Y1055
Pfizer Inc. (US) 000000000000004.054.05% Equities USD USA US7170811035
CVS Health Corp. 000000000000003.933.93% Equities USD USA US1266501006
Humana Inc. 000000000000003.733.73% Equities USD USA US4448591028
Bristol-Myers Squibb Co. (US) 000000000000003.693.69% Equities USD USA US1101221083
UnitedHealth Group Inc. 000000000000003.653.65% Equities USD USA US91324P1021
AbbVie Inc 000000000000003.253.25% Equities USD USA US00287Y1091
Please note that all holdings are delayed with 1 month.

Charges

The charges you pay are used to cover the costs of running the fund, including marketing costs and distribution. These charges reduce the potential growth of your investment.

Charges taken from the fund over a year

One-off charges taken before or after you invest

Other charges *)

*) Other charges are charges which entirely or partially are included in the ongoing charges and/or one-off charges.
MediLife Fund G

Facts about the fund

  • Basic information

    Basic information

    ISIN code FI0008802947
    Listed on stock exchange No
    Sub-fund of Danske Invest
    Fund domicile Finland
    Dividends No
    Management company Danske Invest Fund Management Ltd
    Man. company domicile Finland
    Depositary Skandinaviska Enskilda Banken AB (publ) Helsinki branch
    Minimum initial investment 10 EUR
    Currency EUR
    Price method Single Price
    Legal type UCITS
    Launch date 16.08.2000
    Bloomberg ticker MANMEDK FH
    Marketing permission Finland
    Class of DI MediLife
    Other classes MediLife A
    MediLife Fund D
    MediLife Fund W D
    MediLife Fund W G
    MediLife T
    MediLife W A
    MediLife W K
    MediLife W T
  • Profile

    Profile

    Profile Actively managed
    Type Equity
    Investment area Global
    Benchmark MSCI Health Care (TR) Index
    Recommended investment horizon 7 years
  • Today's figures

    Today's figures

    Total assets, mill. EUR as of 23.09.2022 100.88
    Shareclass total assets, mill. EUR as of 23.09.2022 82.55
    Net asset value (NAV) EUR as of 23.09.2022 2.56769
  • Risk key figures as of 31.08.2022

    Risk key figures as of 31.08.2022

      1 year 3 years 5 years 7 years 10 years
    Avg. annual return (%) 0.97 13.45 12.12 8.45 13.97
    Sharpe Ratio 0.92 0.85 0.58 0.92
    Volatility 14.10 13.89 14.60 14.51
    Tracking Error 4.21 4.26 4.52 4.70
    Information Ratio -0.26 -0.23 -0.32 -0.15
    Calculation is based on end-of-month data.
  • Download documents

Info

Noget gik galt.

Warning

Noget gik galt.

Error

Noget gik galt.